Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Capelle Aan Den Ijssel – page 97

1 543 clinical trials in Capelle Aan Den Ijssel, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Capelle Aan Den Ijssel at a glance
1 543
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 543 trials in Capelle Aan Den Ijssel

Open in trial search

Diffuse large B-cell lymphoma refractory+1

Not recruiting

Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Not recruiting

Study of MK-7684A and Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Multifocal motor neuropathy

Not recruiting

Study on Long-term Safety and Effects of ARGX-117 for Adults with Multifocal Motor Neuropathy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Argenx

Spinal muscular atrophy

Not recruiting

Study on the Safety and Pharmacokinetics of Risdiplam in Infants with Spinal Muscular Atrophy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Risdiplam
  • Sponsor:F. Hoffmann-La Roche AG

Alagille syndrome

Not recruiting

Long-term Study on the Safety and Effectiveness of Odevixibat for Patients with Alagille Syndrome

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

B-cell lymphoma refractory

Not recruiting

Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Chronic kidney disease

Not recruiting

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Non-small cell lung cancer

Not recruiting

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Dimenhydrinate
  • Sponsor:F. Hoffmann-La Roche AG

Chronic myeloid leukaemia

Not recruiting

Study of Bosutinib for Children with Newly Diagnosed or Resistant Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Bosutinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Autoimmune haemolytic anaemia

Not recruiting

Study on Nipocalimab for Adults with Warm Autoimmune Hemolytic Anemia

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Chronic spontaneous urticaria

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Novartis Pharma AG

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Capelle Aan Den Ijssel

What the registry says about research in the country

01 Oncology - Colorectal Studies

Multiple innovative trials focusing on colorectal cancer treatment strategies, including research on liver metastases management and chemotherapy optimization for older patients.

  • Hepatic arterial infusion therapy
  • Dose-adjusted chemotherapy protocols
  • Post-surgical treatment approaches

Advanced research exploring both surgical and medical interventions for improved patient outcomes.

02 Hematology & Breast Cancer

Groundbreaking studies in multiple myeloma treatment protocols and innovative approaches for hormone receptor-positive breast cancer management.

  • Treatment-free interval assessment
  • CDK 4/6 inhibition strategies
  • Endocrine therapy optimization

Focus on developing personalized treatment strategies for better long-term outcomes.

03 Inflammatory & Autoimmune Conditions

Comprehensive research on rheumatoid arthritis management, investigating novel treatment timing and personalized therapeutic approaches.

  • Chronotherapy effectiveness
  • Tailored management protocols
  • Cost-effectiveness analysis

Emphasis on patient-centered outcomes and treatment optimization.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.